Organisation paid for research Program year 2025 Source: CMS Open Payments

Invicro

Neither a doctor nor a teaching hospital

Research payments

$960,812

38 payments

Through program year 2025, Invicro is reported as receiving $960,812 in research payments, across 38 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$651,118	7
2024	Research	$97,680	3
2023	Research	$109,684	7
2022	Research	$91,000	7
2021	Research	$11,329	14

Breakdown

Who paid Research payments · program years 2021–2025

Eli Lilly and Company $889,122 14 payments
UCB Biosciences Inc. $70,650 23 payments
AbbVie, Inc. $1,040 1 payment

Studies the money was for Research payments · program years 2021–2025

Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $373,412 3 payments
A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $215,536 2 payments
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $152,806 4 payments
A Donanemab (Ly3002813) Prevention Study in Participants With Alzheimer's Disease (Trailblazer-Alz 3) $85,194 2 payments
A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinsons Disease $67,650 20 payments
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $55,941 2 payments
Assessment of Safety, Tolerability, and Efficacy of Ly3372689 in Early Symptomatic Alzheimer's Disease $6,234 1 payment
Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy, Safety, and Pharmacokinetics (PK) of Certolizumab Pegol (CZP) for the Treatment of Moderately to Severely Active Crohns Disease (CD) in Children and Adolescents 6 to 17 Years of Age Who Have Had An Inadequate Response to Conventional Therapy $3,000 3 payments
M23-471 Ph1b Target Occupancy PET $1,040 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.